EUVIMEDEUVIMED entdecken
Editorial

Proactive drug safety surveillance should be at the heart of the new Health Data Research Service

Alison Cave, Anthony Harnden

BMJ · 13.05.2026 · 393 · s908

DOI: 10.1136/bmj.s908 ↗

Kurz gefasst

Editorial in der Zeitschrift BMJ, online erschienen am 13.05.2026. Verfasst von Alison Cave und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medicines and Healthcare products Regulatory Agency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The UK’s surveillance system is limited by data that are fragmented, difficult and slow to access, and of variable quality, write AnthonyHarnden and AlisonCave

Autor:innen und Institutionen

  • Medicines and Healthcare products Regulatory Agency.

Zitieren

APA

Cave, A., & Harnden, A. (2026). Proactive drug safety surveillance should be at the heart of the new Health Data Research Service. BMJ, 393, s908. https://doi.org/10.1136/bmj.s908

Vancouver

Cave A, Harnden A. Proactive drug safety surveillance should be at the heart of the new Health Data Research Service. BMJ. 2026;393:s908. doi:10.1136/bmj.s908

BibTeX
@article{Cave2026,
  author = {Cave, Alison and Harnden, Anthony},
  title = {Proactive drug safety surveillance should be at the heart of the new Health Data Research Service},
  journal = {BMJ},
  year = {2026},
  volume = {393},
  pages = {s908},
  doi = {10.1136/bmj.s908}
}
Kostenlos starten →